Taken together, pharmacological inhibition of ASCT2 provoked cell line‐specific effects on the flux of glutamine as a fuel source, yet ultimately led to reduced OCR and cellular lipid levels in both prostate cancer cell lines. Here, SLC1A5 is linked to prostate cancer.